Q1 2025 Earnings Summary
- Strong and progressing pipeline with multiple upcoming catalysts: Roivant Sciences has multiple late-stage programs showing promising results, including IMVT-1402 with a potentially best-in-class profile entering 4 to 5 potential registrational programs this fiscal year, moving up to 10 indications by next fiscal year. They have completed enrollment in their Phase III study of brepocitinib in dermatomyositis, expecting top-line data in the second half of next year. They are also initiating a Phase III study in non-infectious uveitis (NIU). Upcoming data readouts and program unveilings provide significant potential for value creation.
- Financial strength with significant cash reserves and milestone payments: Roivant reported net income of $57 million and net revenues of $55 million for the quarter. They ended the quarter with $5.7 billion in cash and cash equivalents , reflecting a strong financial position to fund pipeline advancement. Additionally, they received a $28 million milestone from the Japanese approval of VTAMA and $110 million from Roche related to Telavant , enhancing their financial resources.
- Growth potential in existing products, particularly VTAMA in atopic dermatitis and psoriasis: VTAMA achieved $18.4 million in product revenue for the quarter, with script volumes up 20% year-over-year. With the upcoming label expansion into atopic dermatitis, which targets a larger patient population and pediatric patients, there is significant opportunity for increased sales. The company is preparing for this launch by targeting new prescribers, such as pediatric allergists and dermatologists.
- Flat sales of VTAMA in psoriasis over the past four to five quarters, remaining in the $18 million to $20 million range per quarter, indicate potential challenges in market uptake and reliance on future approvals for growth.
- Uncertainty in clinical development plans, with the company providing limited details on critical programs, such as the lack of clear go/no-go criteria for the Phase II namilumab study in sarcoidosis , and delayed disclosures on the in-licensed Phase II program, which they plan to unveil in September.
- Increasing operating expenses anticipated due to multiple pivotal studies, including Phase III programs for Immunovant's assets, which may put pressure on financials.
-
LNP Litigation Update
Q: More color on LNP litigation event path ahead?
A: The company is currently in the discovery phase of the LNP litigation, which is expected to continue for a few more months. Together with Moderna, Arbutus, and Genevant, they have requested a moderate extension to address outstanding questions. If approved, summary judgment would occur early next year, followed by a trial a year from now. -
OpEx Guidance with New Trials
Q: How will OpEx evolve with new Immunovant trials?
A: With Immunovant starting several pivotal studies, they expect OpEx to increase. The cost of a Phase III program for an FcRn typically ranges from $80 million to $120 million, plus overhead and personnel costs. Immunovant is well-capitalized for these programs, and the company is excited to be a good partner. -
Sarcoidosis Phase II Potential
Q: Is Phase II sarcoidosis trial potentially registrational?
A: The Phase II sarcoidosis study includes 100 patients and is large enough to serve as at least a pivotal study if successful. There are no approved agents outside of steroids, so the unmet need is significant. Depending on data quality, there may be discussions with regulators. -
Business Development Strategy
Q: Will you focus more on acquiring companies?
A: The company is agnostic to whether they acquire companies or assets. They focus on great programs regardless of form and are currently concentrating on clinical development programs. The distinction between companies or assets isn't significant in their strategy. -
FcRn Asset Launch Plans
Q: Could Roivant launch FcRn asset on its own?
A: It's possible for Roivant to launch their FcRn asset independently. They are aware of a small biotech that successfully launched an anti-FcRn antibody on its own. They are considering all options to maximize the opportunity's value. -
VTAMA in Atopic Dermatitis
Q: Market opportunity and launch prep for VTAMA in AD?
A: They are preparing for the launch by focusing on prescribers not currently targeted, such as pediatric allergists and dermatologists. They'll target pediatric patients, where they'll be alone at launch among novel topicals. They're ensuring their messaging highlights VTAMA's better tolerability profile and differentiated data in AD compared to psoriasis. -
VTAMA Psoriasis Sales Outlook
Q: How can you reinvigorate psoriasis sales for VTAMA?
A: Volumes are building, with a 20% increase versus the same quarter last year. They expect gross-to-net adjustments to normalize, which should reflect in sales numbers. Over time, they anticipate compounding effects as doctors who like the product continue to prescribe more. Psoriasis has the potential to be very meaningful, though it's been a slower build. -
Competitive Dynamics for VTAMA
Q: How do you view competition for VTAMA?
A: The main competition is steroids, not other novel agents. The challenge is changing ingrained doctor behavior by getting them comfortable with new options. In AD, they hope for a label down to age 2, addressing patient populations competitors don't cover. Once-daily application and consistent formulation are advantages. They don't expect significant changes in gross-to-net on AD approval. -
Upcoming Data Catalysts
Q: What's the cadence of data flow this fall?
A: September will be busy with the unveiling of a Phase II asset. Namilumab sarcoidosis data comes later this fall. MG data is expected early next year, followed by CIDP data thereafter. They have a busy 6 to 7 months ahead. -
Phase II Program Unveiling
Q: Any details on the in-licensed Phase II program?
A: They are excited about the program and will share clinical data in September. There is a competitor program with the same mechanism being studied by a big pharma in a different indication. More details will be provided upon unveiling. -
Impact of Market Sell-off on Asset Deals
Q: Does market sell-off change asset negotiation?
A: It depends. They work with various prospective partners affected differently by financial markets. They focus on securing great opportunities at attractive prices and remain excited about future deals.
Research analysts covering Roivant Sciences.